GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older. The approval is the third major global regulatory approval for Epidyolex, GW said in a news release. “The TGA approval is further proof […]
GW Pharmaceuticals cannabis drug gets regulatory OK in Australia is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Read More: GW Pharmaceuticals cannabis drug gets regulatory OK in Australia
Comments are closed, but trackbacks and pingbacks are open.